Nirogacestat Hydrobromide Patent Expiration

Nirogacestat Hydrobromide is Used for treating adult patients with progressing desmoid tumors. It was first introduced by Springworks Therapeutics Inc in its drug Ogsiveo on Nov 27, 2023.


Nirogacestat Hydrobromide Patents

Given below is the list of patents protecting Nirogacestat Hydrobromide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ogsiveo US10590087 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof Aug 09, 2039 Springworks
Ogsiveo US10710966 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof Aug 09, 2039 Springworks
Ogsiveo US10941118 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof Aug 09, 2039 Springworks
Ogsiveo US11504354 Chlorinated tetralin compounds and pharmaceutical compositions Jul 08, 2042 Springworks
Ogsiveo US11612588 Chlorinated tetralin compounds and pharmaceutical compositions Jul 08, 2042 Springworks
Ogsiveo US11807611 Chlorinated tetralin compounds and pharmaceutical compositions Sep 08, 2042 Springworks
Ogsiveo US11820748 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof Aug 09, 2039 Springworks
Ogsiveo US11844780 Chlorinated tetralin compounds and pharmaceutical compositions Sep 08, 2042 Springworks
Ogsiveo US11845732 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof Aug 09, 2039 Springworks
Ogsiveo US11872211 Treatments with nirogacestat May 19, 2043 Springworks
Ogsiveo US11884634 Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide Aug 09, 2039 Springworks
Ogsiveo US11884635 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof Aug 09, 2039 Springworks
Ogsiveo US11905255 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof Aug 09, 2039 Springworks
Ogsiveo US11925619 Treatments with nirogacestat May 19, 2043 Springworks
Ogsiveo US11925620 Treatments with nirogacestat May 19, 2043 Springworks
Ogsiveo US11938116 Treatments with nirogacestat May 19, 2043 Springworks
Ogsiveo US11951096 Treatments with nirogacestat May 19, 2043 Springworks
Ogsiveo US11957662 Treatments with nirogacestat May 19, 2043 Springworks
Ogsiveo US7342118 Imidazole compounds for the treatment of neurodegenerative disorders Aug 18, 2025 Springworks
Ogsiveo US7795447 Imidazole compounds for the treatment of neurodegenerative disorders Aug 18, 2025 Springworks
Ogsiveo US7951958 Imidazole compounds for the treatment of neurodegenerative disorders Mar 11, 2025 Springworks


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳